TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06622603

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Febuxostat
Description: The minimal approved dose of febuxostat is 40 mg/day. We will use 0.5 tablet of febuxostat 40 mg or its placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat
Description: The minimal approved dose of febuxostat is 40 mg/day. We will use 0.5 tablet of febuxostat 40 mg or its placebo.
Study: NCT06184945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Realtime audit and feedback
Description: ICUs randomized to this arm will receive and electronic dashboard that displays realtime ABCDEF bundle performance data

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RN Implementation Facilitator
Description: ICUs randomized to this arm will receive a RN who will assist with ABCDEF bundle implementation
Study: NCT05344989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APNmAb005
Description: Administered by IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APNmAb005
Description: Administered by IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APNmAb005
Description: Administered by IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APNmAb005
Description: Administered by IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APNmAb005
Description: Administered by IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered by IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered by IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered by IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered by IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered by IV infusion
Study: NCT04642586

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: multimodal magnetic resonance imaging
Description: Brain MRI exam (without contrast injection)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: multimodal magnetic resonance imaging
Description: Brain MRI exam (without contrast injection)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood test
Description: Blood test to evaluate cardiovascular risk factors (cholesterol, triglycerides, LDL and HDL-CT, serum creatinine, fasting glucose, serum potassium), .

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood test
Description: Blood test to evaluate cardiovascular risk factors (cholesterol, triglycerides, LDL and HDL-CT, serum creatinine, fasting glucose, serum potassium), .

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: neuropsychological assessment
Description: neuropsychological assessment

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: neuropsychological assessment
Description: neuropsychological assessment
Study: NCT06577766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0638-0355
Description: NNC0638-0355 will be administered as a subcutaneous (s.c. under the skin) injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0638-0355)
Description: Placebo matching NNC0638-0355 will be administered as subcutaneous (s.c. under the skin) injection.
Study: NCT05966961

Intervention type: DEVICE
Intervention: Novosyn® in emergency or elective laparotomy or laparoscopic surgery
Description: Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.

Intervention type: DEVICE
Intervention: Polyglactin 910 in emergency or elective laparotomy or laparoscopic surgery
Description: Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.
Study: NCT04911062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCI without epinephrine
Description: 100 mg administered via injection into the surgical site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX-011 (bupivacaine/meloxicam) dose up to 200 mg/6 mg administered via application into the surgical site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX-011 (bupivacaine/meloxicam) dose up to 200 mg/6 mg administered via application into the surgical site.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer Lock Applicator
Description: Applicator for instillation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer Lock Applicator
Description: Applicator for instillation.
Study: NCT04859894

Intervention type: DIAGNOSTIC_TEST
Intervention: Physiological testing
Description: Cardiopulmonary exercise testing, Lung Function Testing and in some cases echocardiography. 20 subjects will perform DNA-methylation testing.
Study: NCT06157164

Intervention type: OTHER
Intervention: UroLift™ System and Holmium Laser Enucleation of the Prostate (HoLEP)
Description: Simultaneous UroLift™ and Holmium Laser Enucleation of the Prostate (HoLEP) for the Treatment of BPH in Men with Prominent Median Lobe Desiring Preservation of Ejaculation
Study: NCT06549413

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT06620029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMX-001
Description: BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates. BMX-001 (7-28 mg) will be given by subcutaneous (s.c.) injection starting on Day 1, Day 8, Day 15, and Day 22 of each 28-day PTX treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol)
Description: Paclitaxel will be given via IV infusion at a dose = 80 mg/m2 on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle and will be sourced from standard commercial sources. Appropriate pretreatment prior to PTX will be given as per institutional standards. PTX management for any adverse event (AE) in any cycle, reasonably attributed to the chemotherapy agent that requires dose interruption should be managed per package insert, and/or institutional guidelines. Dose modification recommendations are provided in protocol to provide general consistency with dosing. Study Treatment dosing BMX-001 should continue even if the PTX is omitted. The subject may continue on PTX if the AE does not prohibit dosing per institutional practice. Grade 3 or higher infusion PTX reactions or recurrent infusion reactions may require permanent discontinuation of PTX. PTX may be continued in select patients using institutional desensitization protocol.
Study: NCT04679012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Polatuzumab vedotin will be administered as an IV infusion at 1.8mg/kg on Day 1 of each cycle, every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxydaunomycin
Description: Hydroxydaunomycin will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
Study: NCT05401448

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza
Description: Influenza: 0.5 ml of reconstituted Influenza vaccine will be administered intramuscularly in the left upper arm as recommended by the manufacturer.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR vaccines
Description: MMR: 0.5 ml of reconstituted MMR vaccine will be administered intramuscularly in the left upper arm as recommended by the manufacturer.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 0.5 ml of 0.9% NaCl will be administered intradermally in the left upper arm.
Study: NCT05112211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Hyclate
Description: patients administrated with doxycycline tablets 100mg orally per day
Study: NCT05106985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ApplTree reminder app
Description: The reminder app will be introduced to participants to support adherence to chosen goal-related tasks. Reminder app will be introduced following a baseline phase of 10, 16 or 22 days. The duration of the baseline phase will be randomly assigned using an online random number generator.
Study: NCT05341375

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block
Description: The patient was placed in lateral supine position, and the T5 spinous process was moved 2 to 3cm laterally to the operative side as the puncture point, and the pleura and T5 transverse process were observed, and the paraspinal space was observed on the lower lateral side of the transverse process. Using in-plane technique, the needle position was adjusted under ultrasound visualization to reach the paraspinal space. 20ml 0.375% ropivacaine was injected into the suction syringe when there was no blood or gas, and the drug liquid could be seen spreading outside the pleura. Landscape sign appeared, indicating successful block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block
Description: The patient was placed in lateral supine position, and the T5 spinous process was moved 2 to 3cm laterally to the operative side as the puncture point, and the pleura and T5 transverse process were observed, and the paraspinal space was observed on the lower lateral side of the transverse process. Using in-plane technique, the needle position was adjusted under ultrasound visualization to reach the paraspinal space. 20ml 0.375% ropivacaine was injected into the suction syringe when there was no blood or gas, and the drug liquid could be seen spreading outside the pleura. Landscape sign appeared, indicating successful block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Group TE received s-ketamine anesthesia induction dose of 0.3 mg/kg on the basis of TA group. Anesthesia maintenance dose of 0.2ug/kg/h was pumped to 30min before the end of the operation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Measurement of cognitive function
Description: Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE was assessed at one day before surgery, one day after surgery, and three months after surgery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Measurement of cognitive function
Description: Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE was assessed at one day before surgery, one day after surgery, and three months after surgery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Measurement of cognitive function
Description: Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE was assessed at one day before surgery, one day after surgery, and three months after surgery

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The assessment of cognitive function
Description: Participants were assessed for MMSE at the same period as the group C
Study: NCT05544552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TYRA-300
Description: TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TYRA-300
Description: TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TYRA-300
Description: TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.
Study: NCT05774899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-103
Description: First-in-class pan-NOTCH inhibitor, capsule taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-103
Description: First-in-class pan-NOTCH inhibitor, capsule taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-103
Description: First-in-class pan-NOTCH inhibitor, capsule taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-103
Description: First-in-class pan-NOTCH inhibitor, capsule taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: CDK4/6 inhibitor, tablet taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: CDK4/6 inhibitor, tablet taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Per standard care, capsule taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Per standard care, capsule taken orally.
Study: NCT05724056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Idroflog®
Description: The study intervention posology will be based on current labeling of Idroflog®. Participants will be self-administering one drop in each eye 4 times a day every day during the study period.~Administration should follow the label guidelines. Participants should detach a single vial from the strip, remove the flap at the top by rotating it and instill 1 drop into the conjunctival sac of each eye, dropping them from above.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate 0.18% (Vismed®)
Description: The control intervention posology will be based on current labeling of Idroflog®. Participants will be self-administering one drop in each eye 4 times a day every day during the study period.~Administration should follow the label guidelines. Participants should detach a single vial from the strip, remove the flap at the top by rotating it and instill 1 drop into the conjunctival sac of each eye, dropping them from above.
Study: NCT06186830

Intervention type: OTHER
Intervention: Validity and reliability analyses
Description: Validity and reliability analyses will be performed using Cognitive Exercise Therapy Approach Biopsychosocial Questionnaire, Patient Health Questionnaire-9, Patient Health Questionnaire-15, Generalized Anxiety Disorder-7, Short Form-36, Craniomandibular Pain and Disability Inventory, and Mandibular Function Impairment Questionnaire.
Study: NCT04341155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients in experimental arms will receive i.v. dexamethasone 20 mg (4 ampules = 20mL) for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in placebo arms will receive 20 mL normal saline intravenously for 7 days
Study: NCT04514471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unventilated filter cigarettes
Description: Currently marketed unventilated cigarettes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ventilated filter cigarettes
Description: Currently marketed ventilated cigarettes
Study: NCT06522243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-week mindful parenting program
Description: The current study adopts the Mindful Parenting program developed by Prof Susan Bögels (Bögels \& Restifo, 2013), which is an application of mindfulness-based intervention which aims to improve parenting by reducing parents' own stress levels, decreasing parental automatic reactivity, increasing open and unbiased attitudes towards children, and decreasing inter-generational dysfunctional parenting (Bögels et al., 2014). The program consists of eight consecutive weeks of parent groups and one follow-up session two months after the last session. Each parent group will include 15-20 participants. The original Mindful Parenting Program will last for around 3 hours for each session, with the longest practice of 40 minutes. Considering parents recruited in the study may have a higher risk of psychiatric conditions than the general population, each session of mindful parenting group will be reduced to 2 to 2.5 hours with the longest mindfulness practice of 30 minutes (Baer et al., 2019).
Study: NCT06022614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Use Bupivacaine 0.25% Injectable Solution
Description: Group A Patients receiving 20 ml Bupivacaine 0.25% added to 1 ml normal saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution plus Dexmedetomidine
Description: Group B Patients receiving 20 ml Bupivacaine 0.25% added to 1 ml dexmedetomidine
Study: NCT05136339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based mentoring and education sessions
Description: Community-based mentoring and education sessions, group activities, and application of a community toolkit for healthy weight loss delivered by trained Health Promoters from Hispanic and Somali communities to their social networks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based mentoring and education sessions
Description: Community-based mentoring and education sessions, group activities, and application of a community toolkit for healthy weight loss delivered by trained Health Promoters from Hispanic and Somali communities to their social networks.
Study: NCT05224960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: 3 doses of UC-MSCs intravenously at day 1, day 8, day 15.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo(solution without UC-MSCs)
Description: 3 doses of placebo intravenously at day 1, day 8, day 15.
Study: NCT04464720

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cooking Ventilation Intervention
Description: An educational video presentation for the families regarding the importance of ventilation use during and after cooking, and strategies for improving the ventilation during cooking, has been created by Dr. Holm, with input from Youth Research Assistants (YRAs) The youth involvement will help to ensure that the information is presented in a way that will resonate with the local community and will also provide the youth with exposure to developing health education tools. The educational video will be shown to families at the time of the intervention visit and they will receive printed reminder materials of what they have learned.
Study: NCT05295732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMB-001
Description: Topical TMB-001 0.05% QD/BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMB-001
Description: Topical TMB-001 0.05% QD/BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Vehicle
Description: Topical Vehicle
Study: NCT05097768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 0.5mg
Description: The patients will be randomly given the medication by mouth 60 min before administering IANB.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac 10 Mg Oral Tablet
Description: The patients will be randomly given the medication by mouth 60 min before administering IANB.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam 7.5 mg
Description: The patients will be randomly given the medication by mouth 60 min before administering IANB.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: The patients will be randomly given the medication by mouth 60 min before administering IANB.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will be randomly given the medication by mouth 60 min before administering IANB.
Study: NCT05730530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education curriculum
Description: This intervention consists of a 6-week-long nutrition education curriculum aimed at improving fruit and vegetable acceptance and consumption. Sessions will occur within the classroom 3 times per week for 6 weeks. Each week, the sessions will consist of 2 days of teaching activities and 1 day of taste-test activities designed for children to guess various common fruits and vegetables, assemble recipes including 2-4 different fruits and vegetables, and then taste the foods. These activities will be conducted in a full-classroom group setting.
Study: NCT05764291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIT-TEENS
Description: FIT-TEENS is a digital behaviour change intervention which provides information on physical activity and behaviour change support towards physical activity, presented in multimedia format through an online learning platform (EdApp). The contents is developed in Malay language and consist of 10 self-paced modules and activities. The objectives of FIT-TEENS are for the participants to be able to 1) review the definitions and health benefits of physical activity 2) provide an overview of physical activity guidelines 3) write a SMART goal about physical activity 4) be aware of barriers to physical activity and how to overcome them.
Study: NCT05553158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression pants
Description: Similar to compression stockings for the legs which are designed to apply pressure to improve venous return in the legs, compression pants have been designed to apply pressure to pelvic veins to improve the symptoms of Pelvic Congestion Syndrome.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Embolization coils
Description: Embolization coils are used to block the veins they are positioned in. This is a standard treatment offered to patients at The Whiteley Clinic.